Ginkgo Bioworks (NYSE:DNA - Get Free Report) is expected to be announcing its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.23) per share and revenue of $38.70 million for the quarter.
Ginkgo Bioworks Price Performance
Ginkgo Bioworks stock traded up $0.08 during midday trading on Friday, hitting $7.04. 1,049,317 shares of the company were exchanged, compared to its average volume of 1,478,624. The company has a market cap of $408.56 million, a PE ratio of -0.54 and a beta of 1.34. Ginkgo Bioworks has a fifty-two week low of $5.00 and a fifty-two week high of $41.20. The company's fifty day moving average price is $7.24 and its 200-day moving average price is $9.13.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
